Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 18/20 | 0.59 |
| ▸ | SLC5A1 | P13866 | 9/20 | 0.58 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.56 |
| ▸ | SLC5A11 | Q8WWX8 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12285810 | 1.00 | SLC5A2 (0.59) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL12285346 | 0.90 | SLC5A2 (0.66) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL9611976 | 0.90 | SLC5A2 (0.66) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL17189182 | 0.90 | SLC5A2 (0.66) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL12285351 | 0.90 | SLC5A2 (0.61) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL12801854 | 0.90 | SLC5A2 (0.66) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL1038483 | 0.90 | SLC5A2 (0.61) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL1038646 | 0.90 | SLC5A2 (0.67) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL1038645 | 0.90 | SLC5A2 (0.58) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL18265370 | 0.90 | SLC5A2 (0.68) | SLC5A2SLC5A1ADRA2ASLC5A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095197-A1 | METHODS AND COMPOUNDS USEFUL FOR THE PREPARATION OF SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2012-04-19 | — | — | US | disclosed |
| EP-2183263-B1 | METHODS AND COMPOUNDS USEFUL FOR THE PREPARATION OF SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITORS | LEXICON PHARMACEUTICALS INC (US) | 2011-10-26 | — | — | EP | disclosed |
| WO-2009014970-A1 | METHODS AND COMPOUNDS USEFUL FOR THE PREPARATION OF SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITORS | LEXICON PHARMACEUTICALS, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095197-A1 | METHODS AND COMPOUNDS USEFUL FOR THE PREPARATION OF SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITORS | SLC2A2, SLC2A1, SLC5A2 | SLC5A2 3/4885SLC5A1 8/4885ADRA2A 1593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.